Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

5-Year Data on Secukinumab in AS; Oliceridine Not Recommended for FDA Approval

Michele B. Kaufman, PharmD, BCGP  |  November 7, 2018

In a long-term study, secukinumab proved safe and effective for treating ankylosing spondylitis…

Filed under:AnalgesicsAxial SpondyloarthritisBiologics/DMARDsDrug Updates Tagged with:Ankylosing SpondylitisFDAoliceridinePainsecukinumabU.S. Food and Drug Administration (FDA)

Protect Your Practice: Action Update From the ACR’s Insurance Subcommittee

Carina Stanton  |  November 5, 2018

Both private and academic rheumatology practices face payer challenges that put the health of their patients and their practices at risk. To make sure the rheumatologist perspective is heard by payers, “the ACR’s Insurance Subcommittee (ISC) serves as the interface between payers and our members and ACR colleagues,” explains Sean Fahey, MD, a rheumatologist in…

Filed under:American College of RheumatologyInsuranceLegislation & Advocacy Tagged with:ACR Insurance Subcommittee (ISC)downcodingmodifier 25United Healthcare (UHC)

In Memoriam: Mart Mannik, MD

Keith Elkon, MD  |  November 2, 2018

Mart Mannik, MD, professor emeritus, Division of Rheumatology at the University of Washington (UW), passed away on Wednesday, Aug. 22, 2018. Dr. Mannik was born in Estonia and came to the U.S. at age 12 as a refugee from World War II. He received his medical degree from Western Reserve University School of Medicine in…

Filed under:Profiles Tagged with:Dr. Mart Mannikobituary

CMS Proposes New Part B Drug Payment Model

From the College  |  November 2, 2018

Late last month, the Centers for Medicare & Medicaid Services (CMS) released an advance notice of proposed rulemaking (ANPRM), seeking feedback on a potential drug pricing model called the International Pricing Index (IPI) model. This comment solicitation is in alignment with the administration’s blueprint to lower drug costs and reduce out-of-pocket costs, and is an…

Filed under:From the College Tagged with:advance notice of proposed rulemaking (ANPRM)Centers for Medicare & Medicaid Services (CMS)comment solicitationdrug pricing modelInternational Pricing Index (IPI) model

How to Engage Young Adult Patients

Carina Stanton  |  October 30, 2018

Gaps in healthcare are common between the ages of 17 and 21. But simple collaborations between adult and pediatric rheumatologists can go a long way to help young adults stay engaged in their rheumatology care…

Filed under:Practice Support Tagged with:Adolescentspatient carePediatric RheumatologyTransitions

FDA Approves Subcutaneous Tocilizumab for Ages 2–17

Michele B. Kaufman, PharmD, BCGP  |  October 29, 2018

The FDA has approved subcutaneous tocilizumab for treating active systemic juvenile idiopathic arthritis in pediatric patients as young as 2 years old…

Filed under:ConditionsDrug UpdatesPediatric Conditions Tagged with:FDAPediatricsJIAsubcutaneous tocilizumabsystemic juvenile idiopathic arthritistocilizumabU.S. Food and Drug Administration (FDA)

Q&A with New ACR President Paula Marchetta

Kelly Tyrrell  |  October 23, 2018

Paula Marchetta, MD, MA, MBA, became a member of the ACR in 1989, during her rheumatology fellowship at Bellevue Hospital and the New York University (NYU) Medical Center. Just 10 years earlier, rheumatology had been an unlikely path. Dr. Marchetta—with a love of the arts—was pursuing Bachelor’s and Master’s degrees in English. But she found…

Filed under:Profiles Tagged with:ACR presidentPaula Marchetta

ACR Leaders Outline Advocacy Victories, Threats

Thomas R. Collins  |  October 22, 2018

CHICAGO—ACR leaders described a series of looming legislative and regulatory threats to rheumatologists and their patients—including the proposed collapsing of evaluation and management (E/M) coding and potential changes to step therapy rules—and urged everyone in the field to make their voices heard to quash the proposals. They also recounted recent victories in the policy realm…

Filed under:American College of RheumatologyLegislation & AdvocacyMeeting Reports Tagged with:2018 ACR/ARHP Annual Meetingevaluation and management (E/M) codinglegislative and regulatory threatsstep therapy

Plaque Psoriasis Treatments: BMS-986165 Promising & Adalimumab Biosimilar Demonstrates Equivalence

Michele B. Kaufman, PharmD, BCGP  |  October 22, 2018

According to new data, BMS-986165, an oral, selective tyrosine kinase 2 inhibitor, may be safe and effective for treating plaque psoriasis…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabadalimumab-adbmBMS-986165plaque psoriasisTYK2 inhibitortyrosine kinase 2 inhibitor

ARHP Lifetime Achievement Award Winner: Christina H. Opava, PhD, RPT

Keri Losavio  |  October 22, 2018

CHICAGO—Christina H. Opava, PhD, RPT, is the recipient of the 2018 ARHP Lifetime Achievement Award, which was presented (along with the other ACR and ARHP awards) during the opening session of the 2018 ACR/ARHP Annual Meeting on Oct. 20. “Receiving this award is an immense honor,” she tells The Rheumatologist. “My first thought was that…

Filed under:American College of RheumatologyAwardsMeeting ReportsProfessional TopicsProfiles Tagged with:2018 ACR/ARHP Annual MeetingAssociation of Rheumatology Professionals (ARP)AwardsOpava

  • « Previous Page
  • 1
  • …
  • 140
  • 141
  • 142
  • 143
  • 144
  • …
  • 324
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences